The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians

Juan Sebastian Franco, Nicolás Molano-González, Monica Rodríguez-Jiménez, Yeny Acosta-Ampudia, Rubén D. Mantilla, Jenny Amaya-Amaya, Adriana Rojas-Villarraga, Juan Manuel Anaya

Resultado de la investigación: Contribución a RevistaArtículo

16 Citas (Scopus)

Resumen

© 2014 Franco et al.Objectives: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs).Method: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis.Results: Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56- 16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjö gren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis.Conclusions: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients.
Idioma originalEnglish (US)
PublicaciónPLoS One
DOI
EstadoPublished - oct 24 2014

Huella dactilar

lupus erythematosus
Antiphospholipid Syndrome
Systemic Lupus Erythematosus
Antiphospholipid Antibodies
autoimmune diseases
Autoimmune Diseases
Obstetrics
Rheumatoid Factor
autoimmune hepatitis
thyroid diseases
vasculitis
antibodies
rheumatoid arthritis
Systemic Vasculitis
Autoimmune Hepatitis
sclerosis
Dermatomyositis
Biliary Liver Cirrhosis
Systemic Scleroderma
Thyroid Diseases

Citar esto

Franco, Juan Sebastian ; Molano-González, Nicolás ; Rodríguez-Jiménez, Monica ; Acosta-Ampudia, Yeny ; Mantilla, Rubén D. ; Amaya-Amaya, Jenny ; Rojas-Villarraga, Adriana ; Anaya, Juan Manuel. / The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. En: PLoS One. 2014.
@article{aa90afc042a348679c735ab2f8be91ce,
title = "The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians",
abstract = "{\circledC} 2014 Franco et al.Objectives: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs).Method: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis.Results: Although the prevalence of aPL antibodies was 54{\%}, APS was present in just 9.3{\%} of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95{\%} CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95{\%} CI 1.56- 16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95{\%}IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sj{\"o} gren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis.Conclusions: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients.",
author = "Franco, {Juan Sebastian} and Nicol{\'a}s Molano-Gonz{\'a}lez and Monica Rodr{\'i}guez-Jim{\'e}nez and Yeny Acosta-Ampudia and Mantilla, {Rub{\'e}n D.} and Jenny Amaya-Amaya and Adriana Rojas-Villarraga and Anaya, {Juan Manuel}",
year = "2014",
month = "10",
day = "24",
doi = "10.1371/journal.pone.0110242",
language = "English (US)",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",

}

The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. / Franco, Juan Sebastian; Molano-González, Nicolás; Rodríguez-Jiménez, Monica; Acosta-Ampudia, Yeny; Mantilla, Rubén D.; Amaya-Amaya, Jenny; Rojas-Villarraga, Adriana; Anaya, Juan Manuel.

En: PLoS One, 24.10.2014.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians

AU - Franco, Juan Sebastian

AU - Molano-González, Nicolás

AU - Rodríguez-Jiménez, Monica

AU - Acosta-Ampudia, Yeny

AU - Mantilla, Rubén D.

AU - Amaya-Amaya, Jenny

AU - Rojas-Villarraga, Adriana

AU - Anaya, Juan Manuel

PY - 2014/10/24

Y1 - 2014/10/24

N2 - © 2014 Franco et al.Objectives: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs).Method: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis.Results: Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56- 16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjö gren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis.Conclusions: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients.

AB - © 2014 Franco et al.Objectives: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs).Method: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis.Results: Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56- 16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjö gren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis.Conclusions: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients.

U2 - 10.1371/journal.pone.0110242

DO - 10.1371/journal.pone.0110242

M3 - Article

JO - PLoS One

JF - PLoS One

SN - 1932-6203

ER -